Troubled drug buying program congealing; look for July 1 launch

Why This Topic Matters

The article summarizes policy changes that affect how Part B drugs are obtained, billed, and paid under CMS’s competitive acquisition model. It matters to practices and vendors because it outlines the operational and compliance features that could influence whether the program is usable in real-world settings.

Article Sections

1. CMS releases final CAP provisions

   Overview of the agency’s final rule and the status of the program’s planned implementation. The section frames the timing of the rule and the major program changes being discussed.

2. Program enrollment, vendor bidding, and copay handling

   Discussion of how enrollment and vendor participation are structured, along with broad changes affecting patient copay collection, patient communications, and related practice arrangements.

3. Drug administration, wastage, and replacement supply

   Summary of operational topics involving drug delivery, administration, wastage, emergency use of stock, and replacement orders under the program.

4. Claims, payment timing, and patient billing

   Coverage of how vendor and administration claims interact, when payment is triggered, and how patient billing timelines are expected to work.

5. Program background and industry response

   Context on the program’s legislative origins, prior launch difficulties, and reactions from physician and vendor stakeholders to the revised framework.